Raphaël Coscas (Paris, France) talks to Renal Interventions about the first results of the ABISS trial, comparing drug-coated balloon (DCB) with plain-balloon angioplasty for arteriovenous fistula stenosis, which he presented at the Paris Vascular Insights (PVI) conference (23–25 November, Paris, France).
The results were stronger for DCB in the study’s per-protocol analysis, Coscas reports, and were “statistically significant at three, six and 12 months.” He adds that the statistically insignificant results from the intention-to-treat population would have to be reviewed in light of their differences versus the per-protocol analysis outcomes.
